Type 2 diabetes: tools to support therapeutic management ; Diabète de type 2 : outils d'aide à la prise en charge thérapeutique

Introduction: type 2 diabetes (T2D) is a highly prevalent disease with an increase in incidence rates expected in the near future. It is a major public health concern because of its significant economic burden on society and its substantial number of deaths worldwide. The wide variety of scientific data has complexified the management of diabetes. Commercialisation of new drugs such as GLP-1 receptor agonist and SGLT2 inhibitors has brought a change in practice, due to their cardiorenal benefits. The goal of T2D management is no longer solely based on a glucose-centric approach but also includes a holistic approach to patient care. Indeed, there are lots of regions with a gap in specialists that creates lengthened wait times for appointments, forcing general practitionners to become the main actors in T2D management. Hence, the extension of the rights to initiate these traitments. However, they may find themselves overwhelmed by the multiple therapeutic options for prescription as they need to stay constantly updated on recent medical progress. The objective of the study is to determine the tool(s) needed by general practitioners in prescribing these new drugs to their T2D patients in the Val d'Oise (95) department. Methods: in this quantitative descriptive study, we evaluated the prescription of GLP-1 receptor agonist and SGLT2 inhibitors drugs by general practitioners in the Val d'Oise department. Data was collected from 06/22/23 to 01/25/24 via a questionnaire which was used to analyse physicians' profile, the introduction rate and barriers of GLP-1 receptor agonist and SGLT2 inhibitors prescription, the nature of these barriers, and the general practitioners' suggestions to overcome them. Results: 57 general practitioners responded. The average age of participants was 46.6 years old (standard deviation of 11.2 years old) and 63.2% of them were female. There was an average of 59.1 type 2 diabetic patients per general practitioner was reported. Over the past year, the introduction rates of GLP-1 receptor ...